Ceralasertib plus durvalumab does not improve overall survival compared to docetaxel in patients with locally advanced/metastatic NSCLC.

Zongertinib has shown “robust activity” in the treatment of advanced, treatment-naïve, HER2-mutant non-small cell lung cancer.

A major US accreditation group — the Liaison Committee on Medical Education (LCME) — has removed language from its standards that had urged medical schools to teach about health inequities. The change ...

Investigators sought to determine whether weight-based dosing of pembrolizumab could produce outcomes similar to standard fixed dosing for patients with NSCLC.

Investigators sought to identify risks of prescription drug promotion by social media influencers and how current evidence can inform future research and effective policy ...

Adagrasib is effective in older patients with stage IV, KRAS-mutated non-small cell lung cancer, but not in patients with ECOG PS 2.

Names of Medicaid subscribers were sent to states by the Trump administration to see if they were ineligible based on immigration status.

In this analysis, researchers evaluated whether beta blocker use is associated with improved survival in patients with solid tumors.

Investigators assessed differences in efficacy and toxicity of first-line chemotherapy with and without targeted in therapy ...

In this study, researchers aimed to characterize the relationship between major depressive disorder, use of antidepressants, and risk of recurrence in breast cancer patients.

Investigators compared mortality risk among long-term survivors of high-grade serous ovarian cancer versus the general US population to examine how mortality and recurrence trends have changed with ...

LGBTQ+ cancer survivors and their caregivers frequently encounter "minority stress" and suboptimal communication within oncology settings, according to a secondary analysis of the FOCUS Study ...